Genetic modification through oligonucleotide-mediated mutagenesis. A GMO regulatory challenge?

Area of Science:

• Agricultural biotechnology
• Regulatory science
• Molecular biology

Background:

• The European Union (EU) defines genetically modified organisms (GMOs) based on specific technologies used in their development.
• Emerging novel breeding techniques (NBTs) challenge this existing regulatory framework.
• Oligonucleotide-mediated mutagenesis is a key NBT requiring regulatory assessment.

Purpose of the Study:

• To analyze the regulatory and safety implications of using oligonucleotide-mediated mutagenesis for novel organism development.
• To present scientific arguments for excluding organisms developed via this technique from the current EU GMO regulation.
• To inform policy decisions regarding the regulation of NBT-derived organisms.

Main Methods:

• Review of the EU's current GMO regulatory framework.
• Analysis of the technology-based definition of GMOs.
• Scientific assessment of oligonucleotide-mediated mutagenesis and its products.
• Comparative analysis of international regulatory approaches.

Main Results:

• Organisms developed using oligonucleotide-mediated mutagenesis may not fit the current EU GMO definition.
• The technology-based approach faces challenges with the advent of NBTs.
• Excluding these organisms from GMO regulations could foster innovation while maintaining safety.

Conclusions:

• A broad EU-level reflection is necessary to address the regulatory status of novel organisms developed through NBTs.
• Current GMO regulations may not be suitable for organisms produced by oligonucleotide-mediated mutagenesis.
• Policy decisions should aim for international regulatory alignment to avoid trade and research discrepancies.